Your browser doesn't support javascript.
loading
Incobotulinumtoxin A for Sialorrhea in Neurological Disorders: A Real-Life Experience.
Martínez-Poles, Javier; Nedkova-Hristova, Velina; Escribano-Paredes, José Bernardo; García-Madrona, Sebastián; Natera-Villalba, Elena; Estévez-Fraga, Carlos; López-Sendón Moreno, José Luis; Avilés-Olmos, Icíar; Sánchez Díaz, Gema; Martínez Castrillo, Juan Carlos; Alonso-Canovas, Araceli.
Afiliación
  • Martínez-Poles J; Department of Neurology, Hospital Universitario Ramón y Cajal, 28034 Madrid, Spain. javimarpo@gmail.com.
  • Nedkova-Hristova V; Department of Neurology, Hospital Universitario Ramón y Cajal, 28034 Madrid, Spain. velinanh@hotmail.com.
  • Escribano-Paredes JB; Department of Neurology, Hospital Universitario Ramón y Cajal, 28034 Madrid, Spain. bernardoescribano87@gmail.com.
  • García-Madrona S; Department of Neurology, Hospital Universitario Ramón y Cajal, 28034 Madrid, Spain. sebas.gmadrona@gmail.com.
  • Natera-Villalba E; Department of Neurology, Hospital Universitario Ramón y Cajal, 28034 Madrid, Spain. elena.natera.v@gmail.com.
  • Estévez-Fraga C; Department of Neurology, Hospital Universitario Ramón y Cajal, 28034 Madrid, Spain. cefraga@alumni.unav.es.
  • López-Sendón Moreno JL; Department of Neurodegenerative Diseases, UCL Institute of Neurology, London WC1N 3RX, UK. cefraga@alumni.unav.es.
  • Avilés-Olmos I; Department of Neurology, Hospital Universitario Ramón y Cajal, 28034 Madrid, Spain. joselopezsendon@hotmail.com.
  • Sánchez Díaz G; Department of Neurology, Hospital Universitario Ramón y Cajal, 28034 Madrid, Spain. iavilesolmos@gmail.com.
  • Martínez Castrillo JC; Department of Neurology, Hospital Universitario Ramón y Cajal, 28034 Madrid, Spain. gsanchez@salud.madrid.org.
  • Alonso-Canovas A; Department of Neurology, Hospital Universitario Ramón y Cajal, 28034 Madrid, Spain. jmcastrillo@salud.madrid.org.
Toxins (Basel) ; 10(6)2018 05 28.
Article en En | MEDLINE | ID: mdl-29843420
ABSTRACT
Botulinum toxin type A is one of the most useful treatments of sialorrhea in neurological disorders. Evidence for the use of incobotulinumtoxin A (inco-A) in the treatment of sialorrhea is limited. Thirty-six patients with sialorrhea were treated with infiltrations of inco-A into both parotid glands. The severity of sialorrhea was evaluated by the Drooling Severity Scale (DSS), and the Drooling Frequency Scale (DFS). Patients' perceptions of clinical benefit were recorded via the Patient Global Impression of Improvement (PGI-I) scale. Following treatment, there was a significant difference in both the DFS and the DSS (p < 0.001). Clinical benefits on the basis of the PGI-I were present in up to 90% of patients.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Sialorrea / Toxinas Botulínicas Tipo A / Enfermedades del Sistema Nervioso / Fármacos Neuromusculares / Neurotoxinas Límite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Toxins (Basel) Año: 2018 Tipo del documento: Article País de afiliación: España

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Sialorrea / Toxinas Botulínicas Tipo A / Enfermedades del Sistema Nervioso / Fármacos Neuromusculares / Neurotoxinas Límite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Toxins (Basel) Año: 2018 Tipo del documento: Article País de afiliación: España